Biocon Biologics Ltd (BBL), the fully integrated global biosimilars arm of Biocon Ltd, is set to make a major push in oncology, unveiling three new biosimilar cancer therapies at the 44th Annual JP Morgan Healthcare Conference.

 

The new assets—Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda)—expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies. The addition of two PD-1 inhibitors positions the company among the leaders in cost-effective biosimilar oncology treatments.

 

Global sales of these blockbuster biologics highlight the potential impact: Keytruda reached $29.5 billion in 2024, Opdivo $9.3 billion, and Herceptin SC/HYLECTA $1.72 billion. With major patents expiring over the next five years, these biosimilars could dramatically broaden patient access while tapping into an over $75 billion global oncology opportunity, roughly 35% of the market.

 

Biocon Biologics will also integrate as a wholly owned subsidiary of Biocon Limited, a move expected to finalize by March 31, 2026. The integration aims to streamline operations and leverage Biocon’s global commercial network, solidifying its position in diabetes, oncology, and immunology—areas representing nearly 40% of global pharmaceutical revenues.

 

The combined entity will uniquely offer both biosimilar insulins and generic GLP-1 therapies, targeting comprehensive diabetes care for more than 6 million patients across 120+ markets. Post-integration, Shreehas Tambe will serve as CEO & Managing Director of the combined business.

 

“At the 2026 J.P. Morgan Healthcare Conference, we will share how our integration with Biocon Limited strengthens Biocon Biologics’ ability to deliver both biosimilars and generics at global scale,” Tambe said. 

 

“This will position us to better serve patients across diabetes, oncology, and immunology, including expanding access to biosimilar insulins and generic GLP‑1 peptides amid the rising diabetes and obesity burden. 

 

"Guided by a science‑led, R&D approach, we are advancing a strong pipeline with 17 oncology assets to meet varied patient needs. These efforts underscore our commitment to providing affordable, high‑quality medicines for patients around the world.”